The number of people admitted to hospital because they are obese increased by almost 60 per cent last year, according to new figures released today by the NHS Information Centre. The survey also shows that the number of people having weight-loss surgery rose by 55 per cent. Latest figures There were 5, 020 admissions with a primary diagnosis of obesity in 2007/08 in England but this rose to 7, 990 in 2008/09. The findings also reveal a rise in the number of people undergoing weight-loss surgery, such as stomach stapling or having a gastric band fitted, and show that there was an increase between 2006/07 and 2008/09, from 1, 950 procedures to 4, 220.
American Diabetes Association Announces Kansas City, Missouri Native Amy Johnson As 2010 National Youth Advocate
The American Diabetes Association announced that Amy Johnson, 17, of Kansas City, Missouri, will be the Association's 2010 National Youth Advocate. Johnson was diagnosed with type 1 diabetes when she was 12 years old. As the Association's National Youth Advocate, Johnson will spend 2010 meeting with policy makers, promoting the Association's advocacy agenda and reaching out to young people and adults encouraging them to become involved in the fight against diabetes. "Amy's advocacy work on the local, state and federal levels exemplifies a true commitment to the fight to stop diabetes, " said Nash M. Childs, PE, Chair of the Board of the Association.
Young Patients With Type 1 Diabetes: Closed-Loop 'Artificial Pancreas' System Can Improve Blood Sugar Control
An article published Online First and in an upcoming edition of The Lancet reports that the use of 'artificial pancreas' closed-loop insulin delivery systems can improve blood sugar control in patients with type 1 diabetes. In these systems the insulin is delivered in response to changing blood sugar levels. The article is the work of Dr Roman Hovorka, Institute of Metabolic Science, University of Cambridge and Addenbrooke's Hospital, Cambridge, and colleagues. The incidence of Type 1 diabetes has doubled during the past ten years. It is one of the most common chronic childhood diseases. Children and adolescents need lifelong insulin treatment to achieve glucose control that is sufficient to prevent long-term complications.
The Translational Genomics Research Institute (TGen) and Geisinger Health System have announced the signing of a strategic research agreement that provides for a focused look at the gaps in clinical medicine where biomedical research can make a difference. One of the first projects will focus on the causes of obesity, diabetes and other metabolic conditions. Researchers plan to look at the possible genetic reasons why so many Americans are overweight, and why diet, exercise and, specifically, bariatric surgery may fail to significantly reduce excess weight in some patients. TGen, a non-profit biomedical research institute based in Phoenix, will pair its genomic and proteomic research expertise with the clinical excellence and research expertise of Geisinger, a non-profit medical and insurance provider based in Danville, Pa.
Stabilizing high levels of insulin is not an option but a must for everyone, including people with diabetes or pre-diabetes. Why is this important? Because having high insulin levels, which are caused by eating too many carbohydrates, is the starting point for excess body weight that leads to obesity and other chronic diseases such as diabetes, heart disease, kidney failure, etc. I thought I was doing everything I learned correctly, which I was, not ever missing my prescription medicine or five insulin injections every day. However, after two long and painful years, I started to rethink about all of the information I believed, since I was getting worse instead of better.
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill. Access has multiple programs ongoing around use of its Cobalamin technology to facilitate oral absorption of pharmaceuticals, including previously announced collaborations with potential pharma and biotech partners.